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Abstract
Histone deacetylase (HDAC) inhibitors are an emerging class of targeted cancer therapeutics, and little is known
about HDAC expression in gynecologic malignancies. Therefore, we tested the hypothesis whether high-level expres-
sion of class 1 HDACs (HDAC1, 2, and 3) is associated with clinically distinct subsets of ovarian and endometrial
carcinomas. Expression was assessed by immunohistochemistry in a population-based cohort of 465 ovarian and
149 endometrial carcinomas and correlated with clinicopathologic parameters. Each of the HDACs was expressed
at high levels in most ovarian (HDAC1, 61%; HDAC2, 93%; HDAC3, 84%) and endometrial (HDAC1, 61%; HDAC2,
95%; HDAC3, 83%) carcinomas. Further, 55% and 56% of ovarian and endometrial carcinomas, respectively, ex-
pressed all three HDACs at high levels. Such cases were less common among endometrioid subtypes of ovarian
and endometrial carcinomas (36% and 52% positive cases, respectively) compared with high-grade serous sub-
types (64 and 69%, respectively, P < .001). High-level expression of all three HDACs is associated with a poor
prognosis in ovarian endometrioid carcinomas (hazard ratio, 6.7; 95% confidence interval, 1.9–23.3). The indepen-
dent prognostic information and the overall high rate of expression for class I HDACs suggest that these targets
should be explored as predictive factors in ovarian and endometrial carcinomas prospectively.
Neoplasia (2008) 10, 1021–1027
Introduction
Current treatment strategies for ovarian carcinomas with high-risk
histology (e.g., high-grade serous and clear cell subtype) are still in-
effective [1]. Even in stage I/II, 30% to 40% of women with these
neoplasms will die of their disease [2]. For endometrial carcinomas of
the serous and clear cell type, the prognosis is comparably grim [3].
Consequently, novel target-based chemotherapeutic strategies are
urgently needed. Conversely, endometrioid carcinomas of the ovary
and endometrium, which sometimes present synchronously [4], are
less-aggressive tumors compared with their high-risk counterparts.
The great majority of women (approximately 80%) will be cured
by surgery alone because these tumors are frequently organ confined
and tend to metastasize late [5–7]. Because there is no good strategy
to predict the natural course of these tumors, more than 90% of
ovarian endometrioid carcinomas are still treated with platinum-
based chemotherapy, and a large percentage of endometrial endo-
metrioid carcinomas are treated with adjuvant radiotherapy and
chemotherapy [8,9]. Along with the opportunity of subtype-specific
targeted therapy, there is a need to test for novel markers that will help
to classify patient risk independent of currently known risk factors.
Histone modifications are known to be centrally involved in the
malignant transformation of cells and histone deacetylase (HDAC)
inhibitors have proven to be effective as anticancer agents in a broad
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variety of tumors [10–13]. The family of HDACs to date comprises
18 isoenzymes, which, on the basis of structure, could be subclassi-
fied into four classes [11], with class I HDACs being the most thor-
oughly investigated with respect to function and relevance for tumor
formation and progression. Lately, research on these proteins has
gained momentum because small-molecule inhibitors of HDACs
are now available and are currently tested as new antitumor drugs
in late-phase clinical studies for different types of solid tumors
[12,13], including ovarian cancer [14]. In addition, the HDAC in-
hibitor vorinostat has recently been approved for therapy in cuta-
neous T-cell lymphoma [15].
Histone deacetylase inhibitors are known to have profound anti-
tumor effects in both endometrial [16–20] and ovarian carcinoma
cell lines [17,21–23] most likely by inducing cell cycle arrest, apopto-
sis, and differentiation. These drugs act synergistically with paclitaxel-
[24,25] and platinum-based chemotherapeutics [26,27] in vitro.
We have previously found class I HDACs to be highly expressed in
different types of human cancers [28–30]. In addition, class I HDAC
expression was an unfavorable independent prognostic factor in some
of these tumor entities. Currently, little is known about HDAC ex-
pression in gynecologic malignancies [23,31].
In our study, we focused on this apparent lack of translational re-
search in this field and addressed the question whether class I
HDACs are expressed in gynecologic malignancies and whether
expression patterns vary with respect to clinicopathologic and prog-
nostic patient subgroups.
Materials and Methods
Study Population
From a population-based cohort of 3501 patients with ovarian
carcinoma in British Columbia diagnosed between 1984 and
2000, 518 cases were selected on the basis of optimal surgical treat-
ment (i.e., no macroscopic residual tumor after primary surgery) and
were eligible for tissue microarray (TMA) construction after com-
plete gynecopathologic review [5]. Two hundred consecutive cases
of endometrial carcinoma were retrieved from the archives of the
Department of Pathology, Vancouver General Hospital, for the pe-
riod 1983–1998. All cases underwent gynecopathologic review.
Mixed carcinomas were classified according to their highest-grade
component and included if the high-grade component was sampled
on the TMA. Clinical and pathologic data are shown in Table 1.
Both series of cases have been the subject of previous studies
[32,33]. A representative area of each tumor was selected and dupli-
cate 0.6-mm tissue cores were punched to construct a TMA (Beecher
Instruments, Silver Springs, MD).
Adjuvant Therapy and Follow-up
None of the included cases received preoperative radiotherapy or
chemotherapy. Approximately 97% of ovarian carcinoma patients
were treated according to the provincial treatment guidelines of the
British Columbia Cancer Agency [8]. On the other hand, 3% of
patients refused the advised chemotherapy and were excluded from
survival analysis. All patients with endometrial carcinomas were
treated according the BC Cancer Agency treatment recommenda-
tion. All women underwent initial simple hysterectomy and bilateral
salpingo-oophorectomy. For those with documented widespread dis-
ease, debulking surgery as in ovarian carcinomas was performed. Sub-
sequently, radiation was added if the likelihood of local recurrence
was >10%, and chemotherapy with different regimens was given if
the predicted risk of death was >25%. Systematic lymph node dissec-
tion was not routinely performed. Outcomes were tracked through
the Cheryl Brown Ovarian Cancer Outcomes Unit at the British
Columbia Cancer Agency and were available for all patients. Median
follow-up time was 5.1 and 6.2 years for ovarian and endometrial
carcinomas, respectively. Approval for the study was obtained from
the Research Ethics Board of the University of British Columbia.
Immunohistochemistry
Serial 4-μm sections were cut for immunohistochemical analysis
and run through an automated system by Ventana, Tuscon, AZ, as
per manufacturer’s protocol. Polyclonal rabbit anti-HDAC1 antibody
and monoclonal mouse anti-HDAC2 antibody were obtained from
Abcam, Cambridge, UK. Monoclonal mouse anti-HDAC3 antibody
was obtained from Becton Dickinson, Franklin Lakes, CA. Ample
confirmation of antibody specificity has been performed in previous
studies [28–30].
Evaluation of Immunohistochemistry
Tissue microarrays were scored for HDAC1, HDAC2, and HDAC3
by a pathologist (M.K.; scans available online: http://bliss.gpec.ubc.ca/
under OOU ovarian carcinomas, under 02-005 endometrial carcino-
mas). Only nuclear staining within tumor cells was considered for eval-
uation. A four-tiered scoring system was used: 0 for negative cases, +1
for weak intensity, +2 for moderate intensity, and +3 for strong inten-
sity (Figure 1). To optimize for disease-specific survival differences, the
raw data were binarized as follows: the moderate (+2) and strong (+3)
cases were grouped for statistical analysis and assigned the designation 1
and considered as high-level expressors, whereas the completely nega-
tive (0) and weak (+1) cases were considered HDAC low-level expres-
sors and designated as 0. In addition, cases were grouped as being
high for all three HDACs versus others. In total, 53 (10%) ovarian car-
cinoma and 51 (26%) endometrial carcinomas were not interpretable
at least for one marker, and all analyses were restricted to cases with
complete information.
Statistical Analysis
Univariable survival analysis was performed by the generation of
Kaplan-Meier curves, and differences between the groups were as-
sessed using the log rank statistic. Multivariable survival analysis
was performed using the Cox proportional hazards model. Contin-
gency tables and the Pearson χ 2 statistic were used to test the change
in the distribution of HDAC expression across primary cell types.
The Kruskal-Wallis test was used to compare medians for continuous
variables (Ki-67). Spearman rank order correlation was used to deter-
mine whether there was a positive or negative correlation between
Table 1. Distribution of Ovarian and Endometrial Carcinomas across Stage.
Cell Type N (%) Stage I/II (%) Stage III (%) Age (Mean ± SE)
Ovarian carcinoma (all) 465 83 17 58.0 ± 13
High-grade serous 180 (39%) 66 34 60.9 ± 12
Clear cell 122 (27%) 93 7 56.4 ± 13
Endometrioid 114 (24%) 96 4 55.8 ± 13
Mucinous 24 (5%) 100 0 55.4 ± 13
Other 25 (5%) 88 12 60.9 ± 11
Endometrial carcinoma (all) 149 87 13 63.5 ± 13
Endometrioid 127 (85%) 93 7 63.0 ± 13
Serous 13 (9%) 46 54 70.1 ± 8
Clear cell 6 (4%) 83 17 65.5 ± 17
Other 3 (2%) 67 33 58.7 ± 12
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the levels of expression shown by any two types of immunostaining.
All analyses were performed using SPSS v15.0 (SPSS Inc, Chicago,
IL). P values < .05 were considered significant.
Results
Expression Patterns of Class I HDAC Isoforms
in Normal Tissue
HDAC1, HDAC2, and HDAC3 are expressed weakly in nuclei of
ovarian surface epithelium of normal ovaries (n = 5). Expression of all
class I isoforms in normal endometrium and in ovarian endometriosis
was variable but did not exceed moderate staining intensity. Normal
endometrial stroma cells and inflammatory cells, if present, partly
showed moderate staining intensity as well.
Expression Patterns of Class I HDAC Isoforms
in Ovarian Carcinomas
Most ovarian carcinomas expressed high levels of HDAC1 (61%),
HDAC2 (93%), and HDAC3 (84%) in the nuclei of tumor cells
(Figure 1 and Table 2). Cytoplasmic tumor cell expression was not
observed. Stromal cells and inflammatory cells were occasionally pos-
itive. Generally, HDAC2 had the highest expression level in all
tumor subtypes. Expression of class I HDAC isoforms correlated
with each other: HDAC1 with HDAC2 (r = 0.150, P = .001),
HDAC1 with HDAC3 (r = 0.300, P < .001), and HDAC2 with
HDAC3 (r = 0.265, P = .001), suggesting a shared functional regu-
lation. High-level expression of all three isoforms was detected in
55% of ovarian carcinomas with the mucinous subtype of ovarian
carcinoma showing the highest frequency (71%), followed by high-
grade serous (64%), clear cell (54%), and endometrioid subtypes
(36%). These expression levels are indicative of significant differen-
tial expression (P < .001).
Expression Patterns of Class I HDAC Isoforms
in Endometrial Carcinomas
In parallel to the results reported for ovarian carcinomas, most
endometrial carcinomas expressed class I HDAC isoforms in the nu-
clei of tumor cells (HDAC1, 61%; HDAC2, 95%; HDAC3, 83%;
Table 2 and Figure 1). As for ovarian carcinomas, clear cell (83%)
and serous subtypes (69%) showed significantly higher expression rates
for all three HDACs than endometrioid carcinomas (52%, P < .001;
Table 2). In all tumor types, the expression of HDAC2 was highest,
followed by HDAC3 and HDAC1 (Table 2). Expression of HDAC
Figure 1. HDAC expression: (A to D) HDAC1 expression in endometrial endometrioid carcinomas score 0 (A), score 1 (B), score 2 (C),
score 3 (D); (B) insert normal proliferative endometrium. (E) HDAC2 expression in ovarian clear cell carcinoma, score 3. (F) HDAC3
expression in ovarian high-grade serous carcinoma, score 3.
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isoforms showed a moderate degree of correlation with one another:
HDAC1 with HDAC2 (r = 0.321, P < .001), HDAC1 with HDAC3
(r = 0.512, P < .001), and HDAC2 with HDAC3 (r = 0.339, P <
.001). Neither in ovarian nor in endometrial carcinomas a significant
association of HDAC1, HDAC2, or HDAC3 expression with stage
within histologic subtypes was observed (data not shown).
Correlation of Class I HDAC Expression with Proliferation
Because data from cell culture studies suggest a tight interlink be-
tween HDACs and cell proliferation [34,35], we aimed to test this po-
tential association for ovarian and endometrial carcinomas in vivo.
Those tumors showing higher proliferative capacity as determined by
Ki-67 staining usually expressed higher levels of all three class I HDAC
isoforms, in both ovarian (P < .001) and endometrial carcinomas (P <
.001). This significant association was also observed in most of the
major subtypes, with the exception of ovarian endometrioid carcinomas,
which showed a borderline significance of (P = .05; Figure 2).
Correlation of Class I HDAC Expression with
Patient Prognosis
High-level expression of all three class I HDACs was significantly
associated with decreased disease-specific survival in endometrioid
ovarian cancer (Figure 3A; P = .007). In this tumor type, 10-year
disease-specific survival of women with tumors expressing all three
isoforms at high levels was 67% compared with those patients whose
tumors expressed no or only some isoforms with 93%. This effect
was mainly due to a significant association of HDAC1 expression
with prognosis (HDAC1, P = .012; HDAC2, P = .598; HDAC3,
P = .391). In multivariable survival analysis performed under in-
clusion of age, FIGO stage, Silverberg grade, and all three class I
HDACs, HDAC expression retained its independent statistical sig-
nificance (hazard ratio [HR], 6.7, P = .003; Table 3). In serous (Fig-
ure 3B; P = .756), mucinous, and clear cell carcinomas (data not
shown) of the ovary, none of the HDAC isoforms had significant
impact on patient prognosis in univariate survival analysis.
In endometrial endometrioid carcinomas, 10-year disease-specific
survival of women with tumors expressing all three isoforms at high
levels was 63% compared with those patients whose tumors ex-
pressed no or only some isoforms with 83%. Although this was
not statistically significant (Figure 3C ; P = .123), the survival differ-
ence was similar to that observed in their ovarian counterparts (20%
vs 26%). In multivariable analysis under inclusion of age, FIGO stage,
grade, and grouped HDAC expression, class I HDAC expression
showed a trend toward unfavorable prognosis (HR, 2.0, P = .151;
Table 4).
Figure 2. Box-percentile plot of Ki-67 labeling index in ovarian carcinoma subtypes. HG serous (indicates high-grade serous), clear cell,
and endometrioid ovarian carcinoma and endometrioid subtype of endometrial carcinomas subdivided by low (blue) versus high (red)
expression of all three HDACs. P values, Kruskal-Wallis test.
Table 2. HDAC Expression across Ovarian and Endometrial Carcinoma Subtypes.
Cell Type N HDAC1-Positive Cases (%) HDAC2-Positive Cases (%) HDAC3-Positive Cases (%) All Three HDACs-Positive Cases (%)
Ovarian carcinoma 465 61 93 84 55
High-grade serous 180 67 98 92 64
Clear cell 122 64 86 77 54
Endometrioid 114 45 94 78 36
Mucinous 24 83 75 83 71
Other 25 64 100 92 64
Endometrial carcinoma 149 61 95 83 56
Endometrioid 127 58 94 81 52
Serous 13 69 100 100 69
Clear cell 6 83 100 83 83
Other 3 100 100 100 100
Other ovarian carcinomas include nine low-grade serous, six transitional, six undifferentiated, and four adenocarcinoma not otherwise specified.
Other endometrial carcinomas include two small cell carcinomas and one large cell carcinoma.
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Discussion
In this study, we describe a high-level expression of class I HDAC
isoforms in ovarian and endometrial carcinomas. Histone deacetylase
expression is especially prominent in high-grade tumors of serous and
clear cell subtype. In the endometrioid subtype, we show that ex-
pression of the three class I HDACs is an independent prognostic
marker. Reports on in vivo expression of single HDAC isoforms in
ovarian and endometrioid carcinomas are sparse. In a small set of
10 ovarian carcinomas, high expression levels for class I HDACs were
reported [23], which is in line with our results. However, in this co-
hort, it was not possible to test for prognosis or clinical correlations.
Although, in our study, a significant unfavorable prognostic asso-
ciation of class I HDACs for endometrioid tumor subtypes was only
observed for ovarian but not for endometrial carcinomas, the same
trend and similar differences in 10-year survival rates for class I
HDAC expressing groups were evident for tumors arising in both
organs. The reason for the differences between ovarian and endome-
trial carcinomas might be a different assembly of the patient cohorts.
The ovarian carcinoma patients were recruited from a population-
based cohort from British Columbia and restricted to patients with
completely resectable disease after primary surgery. Patients with
endometrial carcinoma were selected from a cohort treated at the
Vancouver General Hospital, which is a specialized center where pa-
tients with high-risk disease are referred for surgery. This is reflected
by a higher number of grade 3 carcinomas in the endometrial endo-
metrioid group (24%) compared to other hospital-based cohorts of
endometrioid endometrial carcinoma (6%) [6] and to the ovarian
endometrioid group (7%, P = .002, Pearson χ 2). In multivariable
analysis, grade and age had a stronger influence on prognosis of
endometrial endometrioid than ovarian endometrioid carcinomas.
Nevertheless, based on presumably similar biology and given the fact
that both tumors occur synchronously in a significant proportion
of patients [4], we think that the findings in ovarian endometrioid
carcinomas could be transferable to their endometrial counterpart.
Larger numbers might be needed to confirm these finding in endo-
metrial endometrioid carcinomas.
Previous immunohistochemical studies of HDAC isoform expres-
sion have been published for gastric [28], colorectal [29], prostate
[30], and breast [34] cancers by our group and others. In colorectal
cancers, class I HDAC expression was associated with poor prognosis
[29]. Because colorectal carcinomas show pathogenetic pathways
(e.g., microsatellite instability, β-catenin mutation, K-Ras mutation)
strikingly similar to endometrioid carcinomas [35,36], similar prog-
nostic effects of HDAC expression might be not surprising.
Figure 3. Kaplan-Meier survival analysis: (A) ovarian endometrioid
carcinomas (N = 114); (B) ovarian high-grade serous carcinomas
(N = 180); (C) endometrial endometrioid carcinomas (N = 127).
P values, log rank test.
Table 3. Univariable and Multivariable Analyses of Disease-Specific Survival for Ovarian Endo-
metrioid Carcinomas (N = 114/15 Events).
Patient Characteristics Risk Factor Univariable Analysis Multivariable Analysis
HR 95% CI P HR 95% CI P
Age * 0.423 * 0.246
Stage I/II 1.0 0.001 1.0 0.0002
III 9.3 2.5–34.0 16.9 3.8–75.4
Silverberg grade 1 1.0 0.264 1.0 0.408
2 1.7 0.5–5.2 1.3 0.4–1.3
3 3.5 0.7–16.7 3.1 0.6–15.7
All three HDACs 0 1.0 0.007 1.0 0.003
1 4.9 1.5–15.7 6.7 1.9–23.3
CI indicates confidence interval; HR, hazard ratio.
*Hazard ratio for age is not available because it is a continuous variable.
Table 4. Univariable and Multivariable Analyses of Disease-Specific Survival for Endometrial En-
dometrioid Carcinomas (N = 123/20 Events).
Patient Characteristics Risk Factor Univariable Analysis Multivariable Analysis
HR 95% CI P HR 95% CI P
Age * 0.0004 * 0.001
Stage I 1.0 0.005 1.0 0.133
II/III 3.6 1.4–8.9 2.1 0.8–5.8
WHO Grade 1 1.0 0.042 1.0 0.052
2 1.0 0.2–4.4 0.5 0.1–2.6
3 3.1 1.2–7.9 2.5 0.9–6.8
All three HDACs 0 1.0 0.123 1.0 0.151
1 2.1 0.8–5.4 2.0 0.8–5.4
*Hazard ratio for age is not available because it is a continuous variable.
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In the entire cohort and in each subtype, class I HDAC expression
is pronounced in highly proliferating tumors as determined by high
Ki-67 labeling index. These data fit well with results from functional
in vitro studies showing that HDAC inhibitors induce cell cycle
arrest in ovarian and endometrial cancer cell lines [17–23].
Our observation that HDAC expression levels vary considerably
and have impact on patient survival in ovarian endometrioid carci-
noma implicates that expression of these proteins might be useful
as a prognostic marker. The absence of or only partial expression
of class I HDACs indicates a very good prognosis (a 93% 10-year
disease-specific survival). Because 94% of these patients received ad-
juvant platinum-based chemotherapy, we are not able to compare the
outcome with a nontreated group. Anecdotally from seven patients,
where adjuvant chemotherapy was not advised, only one woman died
of disease, and this tumor expressed a high level of all three HDACs.
Further, if we estimate the cure rate of women in the chemotherapy
group by using the effectiveness of chemotherapy (33% of patients
are cured by adjuvant therapy) described by the authors of the Action
trial [37], we calculate that 7% died despite chemotherapy and only
4% of our patients were actually cured by chemotherapy; hence,
89% were treated without benefit. Therefore, we would hypothesize
that HDACs’ expression assessment can identify candidates that can
be spared from first-line chemotherapy to minimize overtreatment.
Future larger studies might clarify whether it is necessary to assess
an antibody panel against all three HDACs or whether this prognostic
effect is largely based on the expression of one isoform, e.g., HDAC1.
An even more interesting aspect of our results is that response of
HDAC inhibitors might vary with different expression levels of class I
HDACs. Treatment of tumors expressing low levels of HDACs
might be ineffective because it has been shown that HDAC-negative
tumors caused by the mutation of HDAC genes are resistant to
HDAC inhibitors [38]. Hence, we hypothesize that class I HDAC
expression in ovarian and endometrial carcinomas might be associ-
ated with a positive response to HDAC inhibitors. This would be
especially desirable in endometrioid subtypes, because those patients
that highly express class I HDACs have a compromised prognosis.
Because determination of class I HDAC expression status in tumor
tissue is easy, straightforward, and possible on very small tissue sam-
ples such as the 0.6-mm cores on a tissue microarray, such analysis is
feasible in clinical trials. As we have shown subtype-specific differ-
ences in the prognostic value, it is possible that predictive effects will
also be restricted to specific pathologic subtypes.
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